Immune activation in response to short interfering RNAs (siRNAs) and implications for RNA interference (RNAi) in mammalian cells

Joseph A. Gredell, S. Patrick Walton

Research output: ResearchConference contribution

Abstract

RNA interference (RNAi) is a natural phenomenon observed in many eukaryotic species that can be used to facilitate disease diagnosis, treatment, and an overall understanding of biological processes. It provides a means for potent and primarily specific gene silencing that is initiated by the presence of short interfering RNAs (siRNAs). siRNA is the double-stranded effector molecule (∼21-23 base pairs long) in RNAi that provides the enzyme complex responsible for mRNA cleavage its sequence-specific recognition capability. While this mRNA cleavage was originally thought to be highly specific, it is in fact possible for these siRNAs to elicit a non-specific immune response in the form of interferons, a family of cytokines that mediate antiviral and antigrowth responses. The two known pathways responsible for this immune response are through Protein Kinase R (PKR) and Toll-like Receptor 3 (TLR3). Both proteins recognize dsRNA and signal interferon production as well as stimulation of several transcription factors, such as NF-kB. Use of siRNAs in a therapeutic setting will require complete understanding of these phenomena. Here we have inhibited, in a dose-dependant manner, the green fluorescent protein (GFP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes using siRNA in various human cell lines. In addition, we have measured the immune responses in these cell lines. The important siRNA sequence and structural characteristics are discussed, as are the implications for application of siRNA in the therapeutic context.

LanguageEnglish (US)
Title of host publicationAIChE Annual Meeting, Conference Proceedings
Pages8966
Number of pages1
StatePublished - 2005
Externally publishedYes
Event05AIChE: 2005 AIChE Annual Meeting and Fall Showcase - Cincinnati, OH, United States
Duration: Oct 30 2005Nov 4 2005

Other

Other05AIChE: 2005 AIChE Annual Meeting and Fall Showcase
CountryUnited States
CityCincinnati, OH
Period10/30/0511/4/05

Profile

RNA
Chemical activation
Cells
Proteins
Interferons
Genes
Messenger RNA
Transcription factors
Phosphates
Enzymes
Molecules
Cytokines
Oxidoreductases

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Immune activation in response to short interfering RNAs (siRNAs) and implications for RNA interference (RNAi) in mammalian cells. / Gredell, Joseph A.; Walton, S. Patrick.

AIChE Annual Meeting, Conference Proceedings. 2005. p. 8966.

Research output: ResearchConference contribution

Gredell, JA & Walton, SP 2005, Immune activation in response to short interfering RNAs (siRNAs) and implications for RNA interference (RNAi) in mammalian cells. in AIChE Annual Meeting, Conference Proceedings. pp. 8966, 05AIChE: 2005 AIChE Annual Meeting and Fall Showcase, Cincinnati, OH, United States, 10/30/05.
@inbook{3964c58aed8e457baeef9e589db5d5f6,
title = "Immune activation in response to short interfering RNAs (siRNAs) and implications for RNA interference (RNAi) in mammalian cells",
abstract = "RNA interference (RNAi) is a natural phenomenon observed in many eukaryotic species that can be used to facilitate disease diagnosis, treatment, and an overall understanding of biological processes. It provides a means for potent and primarily specific gene silencing that is initiated by the presence of short interfering RNAs (siRNAs). siRNA is the double-stranded effector molecule (∼21-23 base pairs long) in RNAi that provides the enzyme complex responsible for mRNA cleavage its sequence-specific recognition capability. While this mRNA cleavage was originally thought to be highly specific, it is in fact possible for these siRNAs to elicit a non-specific immune response in the form of interferons, a family of cytokines that mediate antiviral and antigrowth responses. The two known pathways responsible for this immune response are through Protein Kinase R (PKR) and Toll-like Receptor 3 (TLR3). Both proteins recognize dsRNA and signal interferon production as well as stimulation of several transcription factors, such as NF-kB. Use of siRNAs in a therapeutic setting will require complete understanding of these phenomena. Here we have inhibited, in a dose-dependant manner, the green fluorescent protein (GFP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes using siRNA in various human cell lines. In addition, we have measured the immune responses in these cell lines. The important siRNA sequence and structural characteristics are discussed, as are the implications for application of siRNA in the therapeutic context.",
author = "Gredell, {Joseph A.} and Walton, {S. Patrick}",
year = "2005",
pages = "8966",
booktitle = "AIChE Annual Meeting, Conference Proceedings",

}

TY - CHAP

T1 - Immune activation in response to short interfering RNAs (siRNAs) and implications for RNA interference (RNAi) in mammalian cells

AU - Gredell,Joseph A.

AU - Walton,S. Patrick

PY - 2005

Y1 - 2005

N2 - RNA interference (RNAi) is a natural phenomenon observed in many eukaryotic species that can be used to facilitate disease diagnosis, treatment, and an overall understanding of biological processes. It provides a means for potent and primarily specific gene silencing that is initiated by the presence of short interfering RNAs (siRNAs). siRNA is the double-stranded effector molecule (∼21-23 base pairs long) in RNAi that provides the enzyme complex responsible for mRNA cleavage its sequence-specific recognition capability. While this mRNA cleavage was originally thought to be highly specific, it is in fact possible for these siRNAs to elicit a non-specific immune response in the form of interferons, a family of cytokines that mediate antiviral and antigrowth responses. The two known pathways responsible for this immune response are through Protein Kinase R (PKR) and Toll-like Receptor 3 (TLR3). Both proteins recognize dsRNA and signal interferon production as well as stimulation of several transcription factors, such as NF-kB. Use of siRNAs in a therapeutic setting will require complete understanding of these phenomena. Here we have inhibited, in a dose-dependant manner, the green fluorescent protein (GFP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes using siRNA in various human cell lines. In addition, we have measured the immune responses in these cell lines. The important siRNA sequence and structural characteristics are discussed, as are the implications for application of siRNA in the therapeutic context.

AB - RNA interference (RNAi) is a natural phenomenon observed in many eukaryotic species that can be used to facilitate disease diagnosis, treatment, and an overall understanding of biological processes. It provides a means for potent and primarily specific gene silencing that is initiated by the presence of short interfering RNAs (siRNAs). siRNA is the double-stranded effector molecule (∼21-23 base pairs long) in RNAi that provides the enzyme complex responsible for mRNA cleavage its sequence-specific recognition capability. While this mRNA cleavage was originally thought to be highly specific, it is in fact possible for these siRNAs to elicit a non-specific immune response in the form of interferons, a family of cytokines that mediate antiviral and antigrowth responses. The two known pathways responsible for this immune response are through Protein Kinase R (PKR) and Toll-like Receptor 3 (TLR3). Both proteins recognize dsRNA and signal interferon production as well as stimulation of several transcription factors, such as NF-kB. Use of siRNAs in a therapeutic setting will require complete understanding of these phenomena. Here we have inhibited, in a dose-dependant manner, the green fluorescent protein (GFP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes using siRNA in various human cell lines. In addition, we have measured the immune responses in these cell lines. The important siRNA sequence and structural characteristics are discussed, as are the implications for application of siRNA in the therapeutic context.

UR - http://www.scopus.com/inward/record.url?scp=33645638913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645638913&partnerID=8YFLogxK

M3 - Conference contribution

SP - 8966

BT - AIChE Annual Meeting, Conference Proceedings

ER -